ZYN Has MRTP Orders: What the First Pouch Modified Risk Grant Means for Nicotine Suppliers

On June 30, 2026, FDA issued modified risk granted orders to Swedish Match USA for 20 ZYN nicotine pouch products. These are the first modified risk tobacco product (MRTP) orders ever granted in the nicotine pouch category, and as FDA puts it, these 20 products "are the only nicotine pouch products on the U.S. market that have been authorized as MRTPs."

The authorized claim is specific and unusually blunt for a tobacco product: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."

For every other pouch manufacturer, and for the ingredient suppliers behind them, this is no longer a hypothetical about what FDA might allow. It is a decided case with a published evidentiary record. The question for suppliers has moved from "will a pouch ever clear MRTP" to "what does the winning documentation package look like, and can we support one."

What MRTP Is and Why It Is Harder Than PMTA

PMTA authorization, governed by 21 CFR Part 1114, asks whether a product is appropriate for the protection of the public health. The bar is net population-level impact. PMTA authorization does not permit the manufacturer to make reduced-risk claims.

MRTP authorization under Section 911 of the Federal Food, Drug, and Cosmetic Act asks a harder question. The applicant must satisfy FDA on three fronts at once:

1. The product significantly reduces harm and the risk of tobacco-related disease to individual users.
2. Marketing the product with the claim will benefit the health of the population as a whole, accounting for users and non-users.
3. Consumers, including current users and non-users, actually understand the claim as FDA requires.

ZYN's 20 products had already cleared PMTA on January 16, 2025. The MRTP orders cover the same products. What changed is what Swedish Match may now say about them, and FDA described exactly what it had to conclude to permit it: that "the specific modified risk claim is scientifically accurate with respect to these ZYN products, that consumers understand the claim, and that marketing the products with the claim would benefit the population as a whole."

FDA reached that conclusion after weighing "the relative health risks of the products to individuals who use tobacco, consumer understanding and perception of the products marketed with the modified risk claim, data regarding youth risk, and the potential impact to the population," along with the recommendations from the January 22, 2026 Tobacco Products Scientific Advisory Committee meeting, public comments, and other scientific information the agency identified independently.

The Grant Is Conditional, and the Conditions Are the Point for Suppliers

An MRTP order is not a permanent license. FDA attached two conditions that turn modified risk status into an ongoing documentation obligation rather than a one-time filing.

Postmarket surveillance is mandatory. FDA's order "requires Swedish Match USA, Inc. to conduct postmarket surveillance and studies that include an assessment of the MRTP users' behaviors and their understanding of the risk-related information."

The orders expire. In FDA's words, the orders "will expire in five years, before which time the company may request and receive FDA authorization to continue marketing the products as MRTPs." FDA also reserved the right to withdraw them early: "If at any point the agency determines that, among other things, the continued marketing of the products as MRTPs no longer benefits the health of the population as a whole, such as if there is a significant increase in youth uptake, the agency may withdraw the orders."

For an ingredient supplier, a five-year clock with a renewal requirement means the ingredient record cannot go stale. Specifications, impurity profiles, and stability data have to be maintained continuously and be reproducible at renewal, not assembled once and archived.

FDA also drew a boundary that suppliers should quote back to any customer who reads this decision as a category-wide green light: "An order permitting the sale of a modified risk tobacco product (MRTP) refers to specific products, not an entire class of tobacco products." ZYN's orders do nothing for a competitor's pouch, and nothing for a different ZYN SKU that was not in the application.

What the Grant Establishes as the Documentation Standard

The 20 products FDA cleared are ten flavors at two nicotine strengths each (3 mg and 6 mg): Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen. Note what that list contains. Cinnamon, Citrus, and Coffee are non-tobacco, non-mint flavors that carried a modified risk claim through FDA review. Flavor was not disqualifying; the evidence was sufficient.

MRTP applications require product characterization, comparative toxicology, and consumer perception evidence that goes beyond a PMTA. That reaches the ingredient level in specific ways:

Ingredient-level identity and traceability. Components used in synthesis, extraction, or preparation must be documented with purity or grade specification, supplier identification, chemical identifiers such as CAS number or FDA UNII, and target quantities with ranges. FDA's February 2026 product characterization materials set out the expected fields for nicotine specifically: nicotine form, nicotine form name, nicotine source (tobacco-derived or non-tobacco), enantiomeric purity for non-tobacco nicotine, purity or grade, and a target quantity and range with units. For complex ingredients, each single chemical substance is reported separately. Those slides carry FDA's standard disclaimer that they are not a formal dissemination of Agency policy, but they are the clearest published statement of what reviewers expect to see.

HPHC performance against comparison products. This is where the ingredient decides the outcome. FDA's evaluations of authorized pouches have repeatedly turned on constituent levels, finding that the products "contain lower levels of most harmful and potentially harmful constituents (HPHCs) when compared to other oral and smokeless tobacco products, many of which were too low to be quantified." In the January 2025 PMTA authorization, FDA found the ZYN products posed a "lower risk of cancer and other serious health conditions" than cigarettes and most smokeless tobacco products "due to substantially lower amounts of harmful constituents." A finished product cannot report constituent levels below quantification limits if the nicotine going into it carries an uncharacterized impurity load.

Behavioral and consumer perception evidence. Clinical and behavioral studies, plus consumer research confirming that users correctly understand the claim. This sits with the manufacturer, not the supplier, but it is expensive enough that no manufacturer will spend on it while carrying avoidable risk in the ingredient record.

Data that survives renewal. Postmarket surveillance and the five-year expiry mean the ingredient documentation must remain current and defensible for the life of the order.

Why Pharmaceutical-Grade Purity Is the Practical Entry Requirement

The through-line in every FDA authorization decision in this category is the constituent profile. FDA authorized ZYN's PMTA on the strength of substantially lower harmful constituents. It authorized the on! products on the same basis. It granted the modified risk claim after concluding the reduced-risk statement was scientifically accurate for those products.

None of that is reachable with a poorly characterized nicotine input. USP/EP grade nicotine with documented purity and full impurity profiling is not a differentiator in an MRTP-track supply chain. It is the price of entry.

Suppliers providing nicotine salts or nicotine bitartrate dihydrate for pouch applications need to document not just assay purity but the specific contaminants that would elevate HPHC levels downstream, particularly TSNAs. In practice that means batch-specific Certificates of Analysis carrying target specifications with units, quantitative acceptance criteria, and minimum and maximum values rather than a pass/fail line, plus stability data and process documentation that holds up under scrutiny.

What This Means for the Competitive Landscape

ZYN now holds the only authorized reduced-risk claim in the nicotine pouch category, and holds it on 20 specific products for five years subject to surveillance.

Helix Innovations has PMTA authorizations for its on! and on! PLUS products but has not been granted MRTP orders. As of August 19, 2026, FDA's authorized nicotine pouch list held 32 products from these two manufacturers, and only ZYN's 20 carry modified risk orders.

That gap is a commercial asymmetry, and it is the kind competitors fund programs to close. The ingredient supply chain implications follow directly:

MRTP-grade documentation requests will increase. Any manufacturer evaluating a modified risk filing will audit its ingredient suppliers against the record FDA has now shown it accepts. Suppliers who cannot produce purity documentation, batch-level traceability, and constituent data will not be in those programs.

Tobacco Product Master Files become more valuable. A TPMF is a confidential FDA submission containing the supplier's proprietary ingredient and composition data, which manufacturers cross-reference without the supplier disclosing trade secrets. Relatively few nicotine suppliers hold TPMF numbers today.

Documentation becomes a maintained asset. Between postmarket surveillance obligations and a five-year renewal cycle, ingredient documentation for an MRTP-track product is a live record, not an archive.

The Wider Regulatory Picture

Three things are moving on ingredient suppliers at once, and it is worth being precise about the status of each.

First, FDA's nicotine pouch PMTA pilot was closed to new products rather than canceled, and CTP is folding its efficiencies into the review of all nicotine pouch PMTAs. Reviews are getting faster, which shortens the time suppliers have to answer FDA's questions.

Second, the ZYN modified risk orders establish, as a decided matter, what a successful reduced-risk evidence package looks like in this category. That will shape procurement decisions even at manufacturers with no MRTP filing planned.

Third, FDA's proposed Tobacco Product Manufacturing Practice (TPMP) rule, published March 10, 2023 at 88 FR 15174, would introduce quality system requirements at 21 CFR Part 1120. It is a proposal, not law. The most recent Unified Regulatory Agenda entry lists it under Long-Term Actions with a projected final rule date of July 2027, so nothing in it binds anyone today.

The combined effect is a ratchet on documentation expectations. Suppliers building batch-level traceability, TPMF capability, and constituent characterization support now are positioning for an environment that keeps getting more demanding.

Five Steps Ingredient Suppliers Should Take Now

1. Audit your Certificate of Analysis against what FDA reviewers actually flag. Grade certification, assay percentage, full impurity profile including TSNAs, batch-level identification, and, per FDA's roundtable materials, target specifications with units, quantitative acceptance criteria with units, test data averages, and either standard deviation or minimum and maximum values.

2. Evaluate TPMF filing. As manufacturers pursue MRTP or strengthened PMTA submissions, TPMF cross-reference capability becomes a supplier selection criterion.

3. Document constituent characterization for your ingredients as supplied. Every FDA authorization in this category has turned on low constituent levels in the finished product. That data trail starts upstream.

4. Keep manufacturing partner documentation audit-ready. GMP certification, audit history, and process documentation should be available on request, because FDA's requests for additional information now arrive mid-review and on short timelines.

5. Build stability data packages that support renewal, not just filing. MRTP orders expire in five years and carry postmarket surveillance obligations, so ingredient specifications must be demonstrably maintained over time.

Frequently Asked Questions

The category's first modified risk orders are granted, and the record behind them is public. Manufacturers who want parity now have a target to build toward, and the first thing they will audit is the ingredient. NicAlliance supplies USP/EP grade nicotine with batch-level CoA documentation, full impurity profiling, and supply chain traceability built to support both PMTA and MRTP submissions. Request a sample lot with full documentation and evaluate it against your own requirements.